



# Market Announcement

8 August 2024

---

## Actinogen Medical Limited (ASX: ACW) – Trading Halt

### Description

The securities of Actinogen Medical Limited ('ACW') will be placed in trading halt at the request of ACW, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 12 August 2024 or when the announcement is released to the market.

### Issued by

ASX Compliance



8 August 2024

Ms Lisa Banh  
Adviser Listings ASX Compliance (Sydney)  
20 Bridge Street  
SYDNEY, NSW 2000

By email: [tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)

**Request for a trading halt**

Actinogen Medical Limited ACN 086 778 476 (ASX: ACW) (the **Company**), requests that the Company's securities be placed into trading halt with immediate effect.

Pursuant to ASX Listing Rule 17.1, the Company requests the trading halt pending an announcement of the results of the XanaCIDD phase 2a clinical trial.

We anticipate that the trading halt will be required until the earlier of the release of the announcement or no later than 10.00 am AEST on Monday, 12 August 2024.

The Company is not aware of any reason why the trading halt should not be granted by ASX Limited.

The Company is not aware of any other information necessary to inform the market about the trading halt.

Yours sincerely

A handwritten signature in black ink, appearing to read "Peter Webse".

**Peter Webse**  
Company Secretary

***Authorised by the Board of Actinogen Medical***